Path BioAnalytics
PBA, a US-based company, pioneers in precision medicine, developing and tailoring treatments for specific patient groups.
Founded
2014PBA, a US-based company, pioneers in precision medicine, developing and tailoring treatments for specific patient groups.
Founded in Chapel Hill, United States, Path BioAnalytics (PBA) is a pioneering company in the field of precision medicine. The core mission of PBA is to develop and tailor drug treatments for specific patient populations, enhancing the efficacy and personalization of healthcare. Their primary focus is on both precision development—targeting the creation of new treatments for specific groups—and precision treatment—selecting the most effective therapies for individual patients. PBA's innovative approach aims to revolutionize the future of healthcare through personalized medical solutions.
Notable affiliated individuals include experts in biotechnology and healthcare who contribute to PBA's advancements. The company has garnered attention from investors interested in the burgeoning field of precision medicine. Key achievements include significant progress in developing targeted therapies that address unmet medical needs, positioning PBA as a leader in personalized healthcare solutions. Overall, PBA's impact lies in its potential to transform treatment paradigms, offering more effective and customized care for patients worldwide.
Companies similar to Path BioAnalytics include PredxBio, Precision IBD, Praesidia Biologics and Precision Theranostics.
Path BioAnalytics was founded in 2014.
Path BioAnalytics' headquarters is located in Chapel Hill, NC, US.
Path BioAnalytics' most recent funding round was for $100k (USD) in May 2020.
As of May 27, 2020, Path BioAnalytics has disclosed funding of $100k (USD). Undisclosed round amounts are excluded.
Path BioAnalytics has 2 employees as of Feb 4, 2024.
Precision Theranostics
